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Abstract
Background: The consideration of lactate as an active metabolite is a newly emerging and attractive concept.
Recently, lactate has been reported to regulate gene transcription via the inhibition of histone deacetylases
(HDACs) and survival of cancer cells via hydroxycarboxylic acid receptor 1 (HCAR1). This study examined the role of
L- and D-lactate in the DNA damage response in cervical cancer cells.
Methods: Three cervical cancer cell lines were examined: HeLa, Ca Ski and C33A. The inhibitory activity of lactate
on HDACs was analysed using Western blot and biochemical methods. The lactate-mediated stimulation of DNA
repair and cellular resistance to neocarzinostatin, doxorubicin and cisplatin were studied using γ-H2AX, comet and
clonogenic assays. HCAR1 and DNA repair gene expression was quantified by real-time PCR. DNA-PKcs activity and
HCAR1 protein expression were evaluated via immunocytochemistry and Western blot, respectively. HCAR1
activation was investigated by measuring intracellular cAMP accumulation and Erk phosphorylation. HCAR1
expression was silenced using shRNA.
Results: L- and D-lactate inhibited HDACs, induced histone H3 and H4 hyperacetylation, and decreased chromatin
compactness in HeLa cells. Treating cells with lactate increased LIG4, NBS1, and APTX expression by nearly 2-fold
and enhanced DNA-PKcs activity. Based on γ-H2AX and comet assays, incubation of cells in lactate-containing
medium increased the DNA repair rate. Furthermore, clonogenic assays demonstrated that lactate mediates cellular
resistance to clinically used chemotherapeutics. Western blot and immunocytochemistry showed that all studied
cell lines express HCAR1 on the cellular surface. Inhibiting HCAR1 function via pertussis toxin pretreatment partially
abolished the effects of lactate on DNA repair. Down-regulating HCAR1 decreased the efficiency of DNA repair,
abolished the cellular response to L-lactate and decreased the effect of D-lactate. Moreover, HCAR1 shRNA-expressing
cells produced significantly lower mRNA levels of monocarboxylate transporter 4. Finally, the enhancement of DNA
repair and cell survival by lactate was suppressed by pharmacologically inhibiting monocarboxylate transporters using
the inhibitor α-cyano-4-hydroxycinnamic acid (α-CHCA).
Conclusions: Our data indicate that L- and D-lactate present in the uterine cervix may participate in the modulation of
cellular DNA damage repair processes and in the resistance of cervical carcinoma cells to anticancer therapy.
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Introduction
The model of lactate as an active metabolite has emerged
as an attractive concept. The role of lactate as a signalling
factor is supported by observations that lactate mimics
hypoxic conditions, stimulates connective tissue synthesis
and enhances endothelial cell mobility and tumour angio-
genesis [1–3]. Locally produced L-lactate may play a role
in hormone function in an autocrine and paracrine fash-
ion via hydroxycarboxylic acid receptor 1 (HCAR1, also
referred to as GPR81/FKSG80) to exert antilipolytic effects
on adipose tissue [4] or to modulate the activity of primary
cortical neurons [5]. Recently, HCAR1 has been impli-
cated in the regulation of lactate transport mechanisms.
HCAR1 presence enhances pancreatic cancer cell growth
and metastasis [6], and is necessary for survival of the
HER2-positive and the triple-negative breast cancer cells
[7]. The intracellular biological activity of lactate depends
on its cellular uptake, which is facilitated by monocarbox-
ylate transporters (MCTs) [2]. Functional studies have
identified MCT1-4 in the plasma membrane of various
cell types, including uterine cervical cells, and have dem-
onstrated that the bidirectional transport of monocarboxy-
lates (e.g., lactic acid, pyruvic acid and acetic acid) across
the plasma membrane is directed by substrate and proton
concentration gradients [8]. Cells with high glucose me-
tabolism (e.g., most cancer cells) export lactic acid to
maintain intracellular homeostasis, whereas other cells,
such as astrocytes and heart and skeletal muscle cells,
import lactic acid for mitochondrial respiration or as a
substrate for gluconeogenesis (hepatocytes). The weak
inhibitory activity of both L- and D-lactate on histone
deacetylases (HDACs) was also recently reported [9].
Thus, lactate, a natural fermentation product (e.g., butyr-
ate, an established potent HDAC inhibitor), is an import-
ant effector of the epigenetic regulation of chromatin
function. HDACs are involved in acetylation, an important
posttranslational protein modification, and their activity
opposes that of histone acetyltransferases (HATs). In
general, an increasing level of histone acetylation
(hyperacetylation) results in a more relaxed, transcrip-
tionally permissive chromatin conformation, whereas
the reverse action (hypoacetylation) results in a more
condensed, transcriptionally repressive chromatin state.
One of the primary implications of chromatin-HAT/
HDAC remodelling complex interactions is its import-
ant but poorly characterised role in regulating the DNA
damage response (DDR) [10, 11]. HATs and HDACs
are recruited to DNA double-strand break (DSB) sites
to create a repair-proficient chromatin state that or-
chestrates the activity of repair and signalling proteins,
thereby promoting DNA repair processes [12–14]. Fur-
thermore, recent evidence suggests that the coordinated
action of HATs/HDACs may directly affect the DDR by
modulating the activity of key proteins involved in DNA
damage detection and repair, such as DNA-PK [15] and
ATM [16].
The lower female genital tract is an internal structure
of the body in which an extremely high concentration of
lactate is maintained by symbiotic lactic acid bacteria
under physiological conditions [17]. Vaginal secretions
may contain 10–50 mM lactate; approximately 55 % of
vaginally secreted lactate is the D isoform [18]. There-
fore, the modulation of mucosal epithelial cell activity in
the female reproductive tract via the inhibition of
HDACs by lactate represents an appealing topic of in-
vestigation because these cells are constantly exposed to
L-/D-lactate of bacterial origin. This potential modula-
tion is particularly important in the context of patients
with cervical cancer, in which lactate may modulate the
activity of the cervical cancer cells in a manner that al-
ters the effectiveness of chemotherapeutic agents. The
present study reports a novel biological activity of lac-
tate, specifically the modulation of cellular DDR pro-
cesses, in cervical cancer cells. We demonstrated that
concentrations of L- and D-lactate consistent with those
observed in the uterine cervix inhibit class I and II
HDACs, induce the hyperacetylation of H3 and H4 his-
tones, increase chromatin accessibility and significantly
enhance the DNA repair rate in cervical cancer cells, as
evaluated by γ-H2AX and comet assays. The observed
increase in the activity of the DNA repair machinery was
accompanied by a significant enhancement of the sur-
vival of three different cervical cancer cell lines after
chemotherapeutic treatment. In addition, we showed
that all three examined cervical cancer cell lines display
surface expression of HCAR1, which is known to be in-
volved in cell survival. Furthermore, we demonstrated
the essential role of HCAR1 and MCTs in the lactate-
mediated enhancement of cellular DNA repair capacity
and in the resistance of the examined cervical cancer cell
lines to anticancer chemotherapeutics. Importantly, the
present study provides new insight into the role of
microorganism-mammalian cell interactions in the fe-
male genital tract and demonstrates a novel mechanism
underlying the regulation of cellular resistance to geno-
toxins/chemotherapeutics.
Results
L- and D-lactate stimulate the acetylation of histones via
the inhibition of histone deacetylases
Both L- and D-lactate inhibit HDACs in cell-free ex-
tracts [9]. Here, we examined the effect of lactate on
HDAC activity in live cells. Sodium butyrate, an estab-
lished HDAC inhibitor, was used as a positive control.
D-lactate more potently inhibited cellular HDAC activity
than L-lactate (Fig. 1a). The IC50 values for L-lactate,
D-lactate, and butyrate were 124 ± 12, 32 ± 4, and 0.40 ±
0.01 mM, respectively, and were 4-fold (lactate) to 8-fold
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(butyrate) higher than the IC50 values obtained for nu-
clear protein extracts in vitro [9]. Next, we determined
whether lactate induces histone hyperacetylation in cul-
tured HeLa cells in vivo. Both histones H3 and H4 were
acetylated after treatment with lactate or butyrate in a
concentration-dependent manner (Fig. 1b). The effects
of 20 mM L- or D-lactate, the physiological concentra-
tion of lactate in the uterine cervix, on HDAC inhibition
and histone hyperacetylation indicated its relatively weak
activity, as its butyrate equivalent activity was calculated
as a concentration of 0.25–0.5 mM.
Lactate- and butyrate-induced histone hyperacetylation
corresponds to decreased chromatin compactness
Increased histone acetylation at lysine residues due to
the dominance of HAT activity over HDAC activity
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Fig. 1 Lactate induces histone hyperacetylation and alters chromatin compactness by inhibiting HDACs. a HeLa cells were treated with increasing
concentrations of L-lactate, D-lactate, butyrate or NaCl for 2 h before measuring cellular HDAC activity. Basal HDAC activity was subtracted, and
the value observed in the control cells was treated as 100 %. The graph displays the mean ± SEM of HDAC activity from three independent experiments in
the presence of butyrate (black circles), L-lactate (black squares), D-lactate (black triangles) or NaCl (control, black diamonds). b Histone H3 and H4 acetylation
in HeLa cells after 24 h of treatment with L-lactate, D-lactate or butyrate was detected via Western blot analysis. Representative blots of three independent
experiments are shown. c, d The effect of lactate and butyrate on chromatin compactness. HeLa cells were treated with the indicated concentration of
L-lactate, D-lactate or butyrate for 24 h before fixation and Hoechst 33342 staining. Then, the cells were analysed using an ArrayScan VTI HCS Reader.
c Hoechst staining of DNA in representative nuclei and corresponding images after Sobel edge detection transformation. d Graphs of the CVs for
Hoechst fluorescence intensities for all pixels within each nucleus. The CVs are presented as the means ± SEM from four independent experiments.
Statistical significance was evaluated using one-way ANOVA followed by Tukey’s test. *P < 0.05, **P < 0.01 and ***P < 0.001 indicate significant
differences compared to the untreated cells
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reduces the positive charge of histones and disrupts elec-
trostatic interactions between DNA and histones. Exten-
sive acetylations occur on numerous histone tail lysines,
including H3K9, H3K14, H3K18, H4K5, H4K8 and
H4K12 [19]. This process leads to chromatin relaxation.
Because both lactate and butyrate are HDAC inhibitors
that contribute to H3 and H4 pan-acetylation, we exam-
ined the effect of lactate on chromatin compactness. We
studied lactate and butyrate at concentration ranges of
10–20 mM and 0.25–2.5 mM, respectively. After 24 h of
treatment, we observed a decrease in chromatin compact-
ness for both compounds tested, which was observed as a
reduction in the number of distinct spaces within the nu-
cleus (Fig. 1c) after image transformation using the Sobel
edge detection algorithm. Raw images of Hoechst-stained
cells were used to calculate the coefficient of variation
(CV) for Hoechst nuclear fluorescence and to quantify
chromatin compactness (Fig. 1d). Incubating cells with
2.5 mM butyrate significantly decreased the Hoechst CV
by 8 %, whereas cells treated with 20 mM L-lactate or D-
lactate showed a less pronounced decrease in the Hoechst
CV, as their respective Hoechst CVs were 3.2- and 1.7-fold
lower than that of 2.5 mM butyrate.
L- and D-lactate enhance DNA double-strand break repair
following neocarzinostatin, doxorubicin and cisplatin
treatment
Pre-existing histone H3 and H4 modifications can directly
influence the cellular DDR. We studied the kinetics of γ-
H2AX foci formation, a surrogate marker of DNA DSBs,
after exposure to doxorubicin (DOX), cisplatin (CDDP) or
neocarzinostatin (NCS, radiomimetic) to determine the role
of lactate in the cellular DDR. In response to DNA DSBs,
H2AX histones become phosphorylated and form γ-H2AX
histones, which can be detected as nuclear foci via im-
munofluorescence. The kinetics of γ-H2AX foci formation
were determined after the treatment of HeLa cells with lac-
tate (either L- or D-lactate) for 24 h. Cells were then ex-
posed to a chemotherapeutics for 30 min, followed by
measurement of the resolution kinetics of the foci for up to
16 h. Both L- and D-lactate significantly increased the reso-
lution of γ-H2AX foci after treatment with all three chemo-
therapeutics (Fig. 2a-c and Additional file 1, Additional file
2, Additional file 3). Interestingly, D-lactate enhanced the
disappearance of γ-H2AX foci compared to L-lactate in
NCS- and DOX-treated cells, whereas the reverse effect
was observed in CDDP-treated cells. We next examined
whether the observed enhancement of γ-H2AX foci reso-
lution after lactate treatment was accompanied by increases
in the dynamics of DNA DSB repair. We performed comet
assays under conditions similar to those of the γ-H2AX
assay. Both L- and D-lactate significantly enhanced DNA
repair after chemotherapeutic treatment, and the greatest
enhancement was observed after treatment with DOX and
CDDP (Fig. 2d-f and Additional file 4, Additional file 5,
Additional file 6). Furthermore, the effects of D-lactate on
DNA repair dynamics were greater than those of L-lactate
for all studied DNA-damaging agents.
Incubating HeLa cells in L- or D-lactate for 24 h induces
the expression of genes involved in DNA repair
Because incubating cells with lactate led to a less compact
chromatin structure and presumably facilitated DNA access
to the transcriptional machinery, we investigated the effects
of L- and D-lactate on DNA repair enzyme gene expres-
sion, which may have contributed to the observed improve-
ment in the DNA repair rate. We analysed the expression
profiles of the following 23 genes associated with primary
DNA repair mechanisms: base excision repair (LIG3,
XRCC1, PNKP, PARP1, and PARP2), homologous recom-
bination (HR) (RAD51, BRCA1, BRCA2, RAD50, MRE11A
and NBS1), non-homologous end joining (NHEJ) (XRCC6,
XRCC5, PRKDC, LIG4, XRCC4, DCLRE1C, WRN, NHEJ1,
APTX, and PARD3) and DDR (ATM, ATR, TP53, and
MDC1). Incubating cells with lactate for 24 h exerted not-
able effects on the mRNA level of three genes: NBS1, LIG4
and APTX (Table 1); however, the expression levels of the
other genes remained unchanged. L-lactate (D-lactate)
significantly increased the expression of NBS1, LIG4
and APTX by 1.6 (1.9)-, 1.9 (2.1)- and 1.8 (1.5)-fold,
respectively.
Lactate initiates the nuclear activation of DNA-PKcs
Chromatin affects DNA accessibility and provides dock-
ing sites for repair and signalling proteins. Recent evi-
dence has suggested that epigenetic modifications to
chromatin, particularly H3 acetylation, initiate the acti-
vation of DNA-PKcs and its relocalisation from a soluble
nucleoplasmic compartment to a less extractable nuclear
fraction [20]. DNA-PKcs is the key enzyme involved in
NHEJ, which is a DSB repair pathway that is active
throughout the cell cycle (HR pathway is restricted to
the S and G2 phases). Thus, we evaluated the level of
DNA-PKcs phosphorylation upon NCS treatment. The
induction of DNA DSBs promoted the phosphorylation
of DNA-PKcs at Ser2056 [21]; thus, p-DNA-PKcs foci
were observed and used as an in vivo functional marker
of NHEJ activity. Pretreating cells with either lactate iso-
mer led to a significant increase in NCS-induced
pSer2056-DNA-PKcs foci formation (Fig. 3). Stimulating
cells with L- or D-lactate increased the percentage of p-
DNA-PKcs-positive cells by 11 % and 7 %, respectively.
Interestingly, lactate-driven enhancement of DNA-PKcs
activation was also accompanied by higher DNA-PKcs
nuclear immunoreactivity, indicating increased retention
of protein in nucleus (Additional file 7). Taken together,
these results demonstrate that lactate stimulates DNA-
PKcs activity and suggests the substantial involvement of
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NHEJ in the lactate-induced enhancement of DNA
repair.
L- and D-lactate enhance cervical cancer cell survival after
chemotherapeutic treatment
Clonogenic survival assays were performed to investigate
the effect of lactate on NCS-, DOX- and CDDP-mediated
genotoxicity. HeLa cells were treated with 20 mM L- or
D-lactate for 24 h, followed by incubation for 24 h in a
DNA-damaging agent before seeding for colony forma-
tion. L- and D-lactate alone had no significant effect on
HeLa cell survival (94 ± 7 % and 92 ± 10 % compared to
the control, respectively). However, cell survival enhance-
ment was observed when HeLa cells were exposed to
Fig. 2 L- and D-lactate treatment increases DSB repair in cells treated with chemotherapeutics. HeLa cells were incubated in the presence or
absence of 20 mM L- or D-lactate for 24 h, followed by treatment with NCS, DOX or CDDP for 30 min. Then, the cells were allowed to recover for
the indicated period. a, b, c γ-H2AX foci resolution kinetics after chemotherapeutic treatment (2 nM NCS, 2 μM DOX or 20 μM CDDP). The graphs
show the mean number of γ-H2AX foci per cell ± SEM from at least three independent experiments; drug alone (white circles), L-lactate + drug
(black square), D-lactate + drug (black triangles). d, e, f DDR dynamics after chemotherapeutic treatment (5 nM NCS, 2 μM DOX or 20 μM CDDP) as
measured by a neutral comet assay. The basal Olive tail moment (OTM) was subtracted, and the value observed at 0 h was set to 100 %. The
graph shows the mean OTM (% of control) ± SEM from three independent experiments; drug alone (white circles), L-lactate + drug (black square),
D-lactate + drug (black triangles)
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chemotherapeutics in the presence of lactate (Fig. 4a, b
and c). The protective effect of lactate on cell survival was
most prominent at the highest NCS, DOX and CDDP
concentrations tested in the assay (5 nM, 100 nM and
10 μM, respectively); these concentrations were used to
calculate the survival increase factor (SIF) values sum-
marised in Table 2. Surprisingly, the observed effects dif-
fered for specific chemotherapeutic and lactate isomer
combinations. L-lactate exerted a greater protective effect
against NCS, whereas D-lactate exerted a greater protect-
ive effect against DOX (Fig. 4 and Table 2). To confirm
that the observed effect of lactate on the modulation of
cellular resistance to chemotherapeutics is not restricted
to HeLa cells, the clonogenic potential of Ca Ski and
C33A cervical cancer cells was examined in the presence
of lactate and NCS. As shown in Fig. 4a, both lactate iso-
mers moderately enhanced the survival of these cervical
cancer cell types. L-lactate treatment increased the sur-
vival of both Ca Ski and C33A cells treated with NCS by
1.5-fold, whereas D-lactate treatment increased the sur-
vival of Ca Ski and C33A cells by 1.2- and 2.7-fold,
respectively.
HCAR1 abundance and functionality in cervical cancer cell
lines
Recently, the presence of HCAR1 has been shown to be
crucial for pancreatic and breast cancer cell survival [6, 7].
To evaluate the potential role of HCAR1 in the response
of cervical cancer cells to chemotherapeutics, we first
assessed the expression of this receptor in three cervical
cell lines: HeLa, Ca Ski and C33A. The highest cellular
HCAR1 immunoreactivity was found in HeLa cells
(Fig. 5a), reflecting the HCAR1 protein level observed via
Western blot (Fig. 5b). We confirmed the functionality of
HCAR1 expressed in HeLa cells by assessing cAMP for-
mation and Erk phosphorylation [22]. Because HCAR1 is
a Gi/o-coupled receptor that inhibits adenylate cyclase, we
measured the inhibition of cAMP accumulation by lactate
(10–20 mM) in forskolin-stimulated HeLa cells. We ob-
served dose-dependent inhibition of cAMP formation by
lactate treatment in forskolin-stimulated cells and found
L-lactate to be a more active agonist than D-lactate
(Fig. 5c). Stimulating the cells with L-lactate also trig-
gered MAPK signalling (Fig. 5d) within 5 min, as de-
scribed previously [22]. In contrast to its weak
inhibition of cAMP accumulation, D-lactate strongly
stimulated Erk phosphorylation compared to L-lactate,
which showed moderate Erk pathway activation. These
observations suggest that L- and D-lactate may differ in
intrinsic activity towards their target receptors; this
property is described in the literature as functional se-
lectivity, or “bias”, towards certain response pathways
[23]. G-protein coupled receptor-dependent MAPK
pathway activation by lactate was confirmed by treat-
ment of the cells with pertussis toxin (PTX), which un-
couples Gi/o proteins from their receptors, and with a
MAPK inhibitor. Pretreatment with either PTX or
U0126 abolished lactate stimulated Erk phosphoryl-
ation (Fig. 5d).
Pertussis toxin compromises L-lactate-, D-lactate- and
3,5-dihydroxybenzoic acid- stimulated γ-H2AX foci
resolution in cells treated with chemotherapeutics
To assess the role of HCAR1 in lactate-mediated stimu-
lation of DNA repair, we studied the kinetics of γ-H2AX
foci formation in HeLa cells incubated with the HCAR1-
specific agonist 3,5-dihydroxybenzoic acid (3,5-DHBA)
Table 1 Effect of L-lactate and D-lactate on DNA repair gene
expressiona
Gene L-lactate D-lactate
LIG3 1.36 ± 0.23 1.13 ± 0.13
XRCC1 0.95 ± 0.19 0.81 ± 0.13
PNKP 1.22 ± 0.27 1.24 ± 0.13
PARP1 1.07 ± 0.29 0.95 ± 0.23
PARP2 1.31 ± 0.31 1.00 ± 0.29
RAD51 1.06 ± 0.25 0.93 ± 0.18
BRCA1 1.12 ± 0.10 1.08 ± 0.19
BRCA2 1.16 ± 0.17 1.19 ± 0.30
RAD50 1.20 ± 0.20 1.14 ± 0.24
MRE11A 0.82 ± 0.09 0.81 ± 0.14
NBS1 1.60 ± 0.24* 1.88 ± 0.30**
XRCC6 1.01 ± 0.23 0.80 ± 0.26
XRCC5 1.12 ± 0.19 1.01 ± 0.30
PRKDC 1.02 ± 0.28 1.12 ± 0.41
LIG4 1.91 ± 0.17* 2.07 ± 0.46**
XRCC4 0.98 ± 0.21 0.93 ± 0.27
DCLRE1C 1.13 ± 0.16 0.88 ± 0.19
WRN 0.92 ± 0.22 0.73 ± 0.26
XLF 1.02 ± 0.16 0.96 ± 0.10
ATM 1.13 ± 0.22 0.96 ± 0.30
ATR 1.02 ± 0.12 0.88 ± 0.25
TP53 0.91 ± 0.16 0.83 ± 0.15
APTX 1.76 ± 0.28* 1.54 ± 0.26
PARD3 1.01 ± 0.18 1.02 ± 0.18
MDC1 1.04 ± 0.24 1. 54 ± 0.82
aHeLa cells were treated or not treated with 20 mM L-lactate or 20 mM
D-lactate for 24 h before harvesting for RNA isolation. Real-time PCR was
performed as described in the Materials and Methods section. The data are
presented as the mean fold-changes in gene expression ± SEM of treated cells
relative to untreated control cells from at least three independent experiments.
All gene expression levels were normalised to the expression of the housekeeping
genes HMBS and HPRT before calculating the expression ratios. Statistical
significance was evaluated using one-way ANOVA followed by Tukey’s test.
*P < 0.05 and **P < 0.01 denote statistical significance compared to the
untreated cells
Wagner et al. Cell Communication and Signaling  (2015) 13:36 Page 6 of 16
for 24 h followed by treatment with NCS. 3, 5-DHBA
significantly increased the resolution of γ-H2AX foci
(Fig. 6a) after treatment with NCS and its protective ef-
fect was confirmed by neutral comet assay results (Fig. 6b
and Additional file 8). Furthermore, the inhibition of Gi/o
proteins by PTX partially abolished the enhancement of
γ-H2AX foci resolution due to 3, 5-DHBA treatment
(Fig. 6c). Next, we evaluated the effects of PTX pretreat-
ment on the disappearance of γ-H2AX foci in L- and
D-lactate-treated cells exposed to NCS. Pretreatment with
PTX significantly inhibited both the L- and D-lactate-
induced disappearance of γ-H2AX foci in NCS-treated
cells (Fig. 6d, e).
HCAR1 and MCT activity is required for the L- and
D-lactate-mediated enhancement of DNA repair and of
HeLa cell survival
To further explore the mechanism by which HCAR1 is
involved in the lactate-mediated enhancement of DNA
repair and cervical carcinoma cell survival, we studied
the kinetics of γ-H2AX foci formation in cells expressing
reduced level of HCAR1 (Additional file 9). We per-
formed series of experiments using wild type HeLa,
control shRNA- or HCAR1 shRNA-expressing cells, in-
cubated in the presence of either L- or D-lactate and
treated with NCS. The resultant data showed that silen-
cing HCAR1 expression exerted profound effects on
DNA repair kinetics in these cells (Fig. 7a, b). We ob-
served a considerable decrease in DNA repair efficiency
in the HCAR1 shRNA-expressing cells compared to the
control shRNA-expressing cells in the presence or ab-
sence of lactate. HCAR1 knockdown abolished the L-
lactate-induced enhancement of DNA repair (Fig. 7a)
and decreased the stimulatory effects of D-lactate on
DNA repair (Fig. 7b). The present evidence indicates a
correlation of HCAR1 and MCT genes expression with
cancer cell survival in the tumour microenvironment
[6]. Subsequently, we evaluated the functional relevance
of MCTs to the lactate-mediated enhancement of DNA
repair. We found that cells expressing shRNA against
HCAR1 expressed 10, 21 and 60 % lower mRNA levels
of MCT1, MCT2 and MCT4, respectively, compared to
control shRNA-expressing cells (Fig. 7c). Finally, we per-
formed clonogenic and comet assays in the presence of
α-cyano-4-hydroxycinnamic acid (α-CHCA), a classic







































































Fig. 3 Lactate treatment initiates DNA-PKcs activation. HeLa cells were incubated in the presence or absence of L-lactate or D-lactate for 24 h,
exposed to NCS (2 nM) for 30 min, and allowed to recover for 4 h before staining with a phospho-specific antibody directed against Ser2056 of
DNA-PKcs. a Immunocytochemical staining of DNA-PKcs phosphorylation at S2056. Each image shows representative microscopic area for the
particular treatment from the same experiment. b The graphs show the means ± SEM of the percentage of cells containing more than six foci
from three independent experiments. Statistical significance was evaluated using one-way ANOVA followed by Tukey’s test.*P < 0.05, **P < 0.01
and ***P < 0.001 indicate significant differences compared to the untreated cells
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stimulatory effects of lactate on DNA repair and cell sur-
vival depend on intracellular lactate. HeLa cells were
treated with α-CHCA (2 mM) for 1 h before exposure to
NCS with or without lactate. α-CHCA pretreatment had
no significant effect on basal DNA repair or cell survival
after exposure to NCS. However, α-CHCA abolished the
L- and D-lactate-mediated increases in DNA repair after
5 nM NCS exposure as evaluated by the comet assay
(Fig. 7d). Furthermore, α-CHCA significantly suppressed
the protective effects of L- and D-lactate on cell survival
after NCS treatment (Fig. 7e). Our results suggest that
extracellular lactate transport by MCTs coordinated by
HCAR1 is responsible for the observed effects of lactate
on the enhancement of DNA repair and cell survival.
Discussion
Recent evidence has identified lactate as an active metab-
olite and a pseudo-hormone that coordinates metabolic
processes at the systemic and cellular levels. L-lactate
produced by malignant tumours may be a crucial com-
ponent enabling significant cancer cell growth and
resistance [6, 7, 24]. Latham and colleagues have dem-
onstrated that both L- and D-lactate inhibit HDACs and
promote changes in gene expression in a manner simi-
lar to the established HDAC inhibitors butyrate and
trichostatin A [9]. This evidence strongly suggests that
lactate is involved in the posttranslational modifications
of histone and non-histone proteins and that lactate
participates in the modulation of protein signalling and
activity. Our study is the first to demonstrate that pre-
treating cervical cancer cells with lactate improves their
DNA repair capacity and enhances cell survival follow-
ing chemotherapeutic treatment. In the present study,
we incubated cervical cancer cells with 10–20 mM lac-
tate to mimic physiological lactate concentrations in the
lower female genital tract environment. Lower female
genital tract epithelium-associated bacterial flora are
the major producers of the L- and D-lactate found in vagi-
nal secretions (at concentrations as high as 10–50 mM).
Biochemical experiments demonstrated that incubating
HeLa cells with L- or D-lactate decreased the activity of
class I and II HDACs in living cells as expected. The in-
hibition of HDACs by lactate was accompanied by the
acetylation of histones H3 and H4 and by a decrease in
DNA compactness (Fig. 1). Incubating cells with lactate
for 24 h evoked a transcriptionally permissive chromatin
conformational state and a subsequent significant up-
regulation of important genes involved in DNA DSB
Fig. 4 Lactate treatment enhances the resistance of cervical cancer cells
to chemotherapeutics. Cells were incubated in the presence or absence
of 20 mM L- or D-lactate for 24 h, followed by treatment with NCS (a),
DOX (b) or CDDP (c) for the next 24 h in lactate-containing medium
before seeding for colony formation in drug-free medium. The results
are expressed as the means ± SEM of three independent experiments;
cells treated with vehicle (white columns), cells treated with L-lactate
(grey columns), cells treated with D-lactate (striped columns). Statistical
significance was evaluated using one-way ANOVA followed by Tukey’s
test. *P < 0.05, **P< 0.01 and ***P< 0.001 indicate significant differences
compared to the untreated cells
Table 2 Modulation of the chemoresistance of cervical cancer cells by lactate
Cell line Drug SFa SFL SFD SIFL SIFD
HeLa NCS 0.14 ± 0.02 0.33 ± 0.01* 0.23 ± 0.04 2.37 ± 0.44 1.66 ± 0.59
HeLa DOX 0.10 ± 0.01 0.18 ± 0.04* 0.27 ± 0.00*** 1.86 ± 0.52 2.77 ± 0.29
HeLa CDDP 0.01 ± 0.001 0.033 ± 0.001 0.027 ± 0.006* 3.37 ± 1.42 2.79 ± 0.82
Ca Ski NCS 1.04 ± 0.05 1.54 ± 0.18 2.82 ± 0.23*** 1.49 ± 0.25 2.72 ± 0.36
C33A NCS 0.23 ± 0.03 0.35 ± 0.06 0.28 ± 0.07 1.52 ± 0.44 1.21 ± 0.45
aSF survival fraction for 5 nM NCS, 100 nM DOX or 10 μM CDDP; SFL,D survival fraction after L-lactate or D-lactate pretreatment; SIF survival increase factor. The SIFs
were calculated using the equation SIFlactate = SFlactate/SF; the means of at least three independent experiments are reported. Statistical significance was evaluated
using one-way ANOVA followed by Tukey’s test. *P < 0.05 and ***P < 0.001 indicate significant differences between SFlactate and SF
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repair, including LIG4, NBS1, and APTX (Table 1). Indeed,
mutation of the genes encoding DNA ligase IV (LIG4),
Nibrin (NBS1) or Aprataxin (APTX) results in DDR disor-
ders, specifically LIG4 syndrome, Nijmegen breakage
syndrome (NBS) and Ataxia oculomotor apraxia-1, in
association with increased radiosensitivity [25–27]. Re-
cent evidence suggests that HATs and HDACs are re-
cruited to DNA DSB sites to create a repair-proficient
chromatin state that orchestrates the activity of repair
and signalling proteins, thereby promoting DNA repair
processes [12–14]. Our study is the first to demonstrate
that L- and D-lactate stimulate the activation of DNA-
PKcs (Fig. 3), the essential component of NHEJ, although
previous studies have demonstrated that histone H3
acetylation induced by trichostatin A [20] or histone
acetylation in response to DSBs [15] facilitates DNA-PKcs
activation. Thus, it is conceivable that such up-regulation
of DNA repair mechanisms via a lactate-elicited increase
in the activity of DNA-PKcs and in the transcriptional ex-
pression of DNA ligase IV, Nibrin and Aprataxin could
translate into accelerated processing of DNA damage. In-
deed, L- and D-lactate improved the kinetics of γ-H2AX
foci formation and resolution and the dynamics of DNA
DSB repair after exposure to NCS, DOX or CDDP. Both
lactate isomers significantly enhanced DNA repair, al-
though D-lactate, a stronger HDAC inhibitor, was found
more effective than L-lactate (Fig. 2). The observations of
lactate-induced enhancement of DNA repair were further
supported by the protective effects of lactate on cell sur-
vival. We showed that lactate increased the survival of
three cervical cancer cell lines: HeLa, Ca Ski and C33A;
however, the Ca Ski and C33A cell lines were less prone to
lactate-induced modulation than the HeLa cell line (Fig. 4).
Interestingly, the enhancement of cervical cancer cell sur-
vival by L-lactate treatment corresponded to the HCAR1
protein level in the respective cell lines (Fig. 5a, b). Of the
three examined cell lines, the HeLa cell line, demonstrat-
ing the most abundant expression of HCAR1, showed the
most prominent protective effect of lactate on clonogenic
survival, as its survival fraction (SF) increased by 2.4-fold
Fig. 5 Cervical carcinoma cells express HCAR1 and respond to stimulation with lactate. a Immunocytochemical staining of HCAR1; scale bar,
10 μm. b Representative Western blot for the HCAR1 protein level in three cervical carcinoma cell lines (HeLa, Ca Ski and C33A). The HCAR1
protein level was quantified using densitometry and presented as relative means ± SEM of HCAR1/β-actin ratio normalised to HeLa cells,
calculated from three independent experiments. c L- and D-lactate inhibit cAMP accumulation in forskolin-stimulated HeLa cells. Cyclic AMP was
measured in cells treated with L- or D-lactate for 30 min in the presence of 10 μM forskolin. The results are expressed as the means ± SEM of at
least three independent experiments. d Stimulation of Erk phosphorylation by L- or D-lactate is sensitive to PTX and U0126. Serum-starved HeLa
cells were pretreated or not with PTX (100 ng/ml) or U0126 (10 μM) and stimulated with L- or D-lactate for 5 min. Representative blots of three
independent experiments are shown
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after L-lactate treatment, which was higher than that of
the Ca Ski and C33A cell lines (both 1.5-fold) (Table 2).
Our observations are in line with recent evidence indicat-
ing that the HCAR1 levels correlate to the rates of cancer
tumour growth and metastasis [6]. In the present study,
we demonstrated that cervical cancer cell lines display
HCAR1 surface expression and that both lactate isomers
induced signalling pathways in a receptor-dependent fash-
ion (Fig. 5a-d). Interestingly, L-lactate preferentially stimu-
lated Gi-mediated pathway, inhibited forskolin-induced
intracellular cAMP and slightly activated MAPK pathway,
while D-lactate triggered MAPK pathway only. These ob-
servation suggest that L- and D-lactate may differ in in-
trinsic activity towards HCAR1 resulting in differential
activation of signal transduction pathways associated
with this receptor [23]. In addition, incubating HeLa
cells with the HCAR1 agonist 3,5-DHBA improved the
kinetics of γ-H2AX foci formation and resolution to a
similar but smaller extent than lactate. As expected,
uncoupling G-proteins from HCAR1 via pretreatment
with PTX decreased L-lactate-, D-lactate- and 3,5-
DHBA-stimulated γ-H2AX foci disappearance in cells
exposed to NCS (Fig. 6c-e). Furthermore, experiments
using HCAR1 shRNA-expressing cells showed that si-
lencing HCAR1 exerted profound effects on DNA re-
pair kinetics, which were observed as considerably
diminished γ-H2AX foci disappearance kinetics in the
presence or absence of lactate (Fig. 7a, b). Based on the
Fig. 6 Stimulation of γ-H2AX foci resolution with L-lactate, D-lactate and 3,5-dihydroxybenzoic acid (3,5-DHBA) in cells treated with neocarzinostatin is
compromised by pertussis toxin pretreatment. HeLa cells were incubated in the presence or absence of 500 μM 3,5-DHBA, 20 mM L-lactate or 20 mM
D-lactate for 24 h, followed by treatment with 2 nM NCS for 30 min. Then, the cells were allowed to recover for 4 h unless otherwise indicated.
a γ-H2AX foci resolution kinetics after 3,5-DHBA treatment. The graphs show the mean number of γ-H2AX foci per cell ± SEM from at least three
independent experiments; drug alone (white circles), 3,5-DHBA + drug (black circles). b DSB repair after NCS treatment was measured by a neutral comet
assay. HeLa cells were incubated in the presence or absence of 3,5-DHBA for 24 h, followed by treatment with 5 nM NCS for 30 min. Then, the cells
were allowed to recover for 2 h. The basal Olive tail moment (OTM) was subtracted, and the value observed at 0 h was set to 100 %. The graph shows
the mean OTM (% of control) ± SEM from three independent experiments. c, d, e γ-H2AX foci resolution in HeLa cells pretreated with 100 ng/ml PTX
for 1 h before incubation in the presence or absence of 3,5-DHBA (c), L-lactate (d) or D-lactate (e). The graphs show the mean number of γ-H2AX foci
per cell expressed as a % of control ± SEM from at least three independent experiments. Statistical significance was evaluated using Student’s t-test.
*P < 0.05 and **P < 0.01 indicate significant differences compared to the untreated cells
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study by Roland and co-workers [6] HCAR1 is implicated
in the regulation of lactate transport mechanisms. Our
study using HCAR1 shRNA-expressing HeLa cells re-
vealed that silencing HCAR1 affects the mRNA level of
MCT4 (Fig. 7c), which facilitate the cellular uptake of
lactate. Complimentary experiments performed using
α-CHCA, a classic MCT inhibitor [3], confirmed that the
observed stimulatory effect of lactate on DNA repair and
cell survival depends on its intracellular activity (Fig. 7d, e).
Taken together, these data demonstrated that lactate trans-
port by MCTs is crucial for its intracellular activity, which
leads to chromatin rearrangement and enhanced DNA re-
pair and cell survival. However, although the observed
lactate-induced stimulation of DNA repair activity seems
to result from its inhibitory activity on HDACs, we cannot
rule out the possibility that other HCAR1-dependent re-
sponses may affect cellular DNA repair capacity. It is worth
noted that D-lactate induced marked Erk phosphorylation
via PTX-sensitive pathway compared to slight MAPK sig-
nalling activation by L-lactate (Fig. 5d). A detailed study by
Li and co-workers [22] showed that upon HCAR1 activa-
tion, the dissociation of the Gβγ subunit from the Gi pro-
tein subsequently induces Erk activation via two distinct
pathways: a PKC-dependent pathway and an IGF-1R
transactivation-dependent pathway [22]. Because IGF-1R
and EGFR are known for their cross-talk [28] and both
receptors are involved in HR and NHEJ [28, 29], the in-
volvement of the HCAR1/IGF-1R/EGFR axis in DNA
repair requires further investigation.
Conclusions
In the present study, we reported a new potential mechan-
ism underlying the interaction between lower female
genital tract microbiota and cervical epithelial cells under
physiological conditions. Vaginal and ectocervical micro-
biota not only protect against pathogen colonisation by
acidifying the mucosa using lactic acid but also, according
to our results, appear to modulate the activity of the
cervical cancer cells in a manner that alters its resistance
to chemotherapeutics. Our data indicate a novel mechan-
ism by which lactate modulates the cellular DNA damage
repair process in cervical cancer cells; in this mechanism,
L- and D-lactate are actively transported across the cell
membrane by MCTs to intracellular compartments, lead-
ing to the inhibition of class I and II HDACs. This inhib-
ition results in the hyperacetylation of histones H3 and H4,
chromatin relaxation, DNA repair gene up-regulation and
DNA-PKcs activation in the nucleus. Thus, lactate creates
a DNA repair-proficient environment that stimulates DNA
repair dynamics and significantly enhances cervical carcin-
oma cell survival after drug treatment. Furthermore, we
also showed that lactate-induced DNA repair enhancement
is regulated by the HCAR1/MCT axis, as lactate receptor
down-regulation or MCT inhibition notably affects DNA
repair efficiency. We suggest that the enhancement of
DNA repair machinery activity by lactate may account for
the increased resistance of malignant cervical tumours to
standard clinical therapy (such as cisplatin and ionising
radiation). Thus, targeting lactate-mediated signalling in
cervical cancer environment, e.g. by locally delivered MCTs
inhibitors and/or HCAR1 antagonist, might improve
efficacy of anticancer therapy.
Materials and methods
Chemicals
All chemicals were purchased from Sigma-Aldrich
(St. Louis, MO, USA) unless otherwise stated. Doxorubicin,
forskolin, α-CHCA and U0126 were dissolved in
anhydrous DMSO and added to cells at a final DMSO
concentration of 0.5 % (v/v). Control cells were incu-
bated in 0.5 % DMSO alone.
Cell culture
The HeLa, Ca Ski and C33A human cervical cancer cell
lines were purchased from American Type Culture Collec-
tion (ATCC, Manassas, VA, USA) and were authenticated
by short tandem repeat profiling (LGC Standards, UK) at
the end of the study. HeLa cells were cultured in DMEM,
and Ca Ski and C33A cells were cultured in RPMI medium
(Life Technologies, Carlsbad, CA, USA) supplemented
with 10 % foetal bovine serum (PAA Laboratories GmbH,
Pasching, Austria) and antibiotics (Life Technologies) at
(See figure on previous page.)
Fig. 7 HCAR1 and MCT activity is required for the L- and D-lactate-mediated enhancement of DNA repair and cell survival. a, b γ-H2AX foci resolution
kinetics in control and HCAR1 shRNA-expressing HeLa cells incubated in the presence or absence of (a) 20 mM L-lactate or (b) 20 mM D-lactate for
24 h and then treated with 2nM NCS for 30 min.; drug alone (white circles), lactate + drug (black circles). c The relative mRNA level of MCT1, MCT2 and
MCT4 in control (white column) and HCAR1 shRNA-expressing HeLa cells (black column). d, e Pretreatment of HeLa cells with the MCT inhibitor α-CHCA
abolishes the modulatory effect of lactate. d HeLa cells were pretreated with 2 mM α-CHCA for 1 h before incubation in the presence or absence of
L-lactate (20 mM) or D-lactate (20 mM) for 24 h. Then, the cells were exposed to NCS (5 nM) for 30 min and allowed to recover for 2 h before harvesting
for the neutral comet assay. The basal OTM was subtracted, and the value observed at 0 h was set to 100 %. The graph shows the mean OTM± SEM
from three independent experiments; cells treated with vehicle (white columns), cells treated with α-CHCA (black columns). e The clonogenic survival of
HeLa cells pretreated with 2 mM α-CHCA for 1 h before incubation in the presence or absence of L-lactate (20 mM) or D-lactate (20 mM) for 24 h. Then,
the cells were exposed to NCS (5 nM) for the next 24 h and seeded for colony formation in drug-free medium; cells treated with vehicle (white columns),
cells treated with α-CHCA (black columns). Statistical significance was evaluated using Student’s t-test. *P < 0.05 and **P < 0.01 indicate significant
differences compared to the corresponding counterparts. The results are expressed as the means ± SEM of three independent experiments
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37 °C in a humidified atmosphere containing 5 % CO2.
The cells were routinely tested for mycoplasma contamin-
ation and were passaged every 3 days using TrypLE
Express (Life Technologies).
HDAC assay
The inhibitory effects of lactate and butyrate on cellular
HDAC activity were measured using an HDAC-Glo I/II
Assay Kit (Promega, Madison, WI, USA) for class I/II
HDACs according to the manufacturer’s protocol.
Briefly, HeLa cells grown on 96-well plates were treated
with sodium L-lactate, sodium D-lactate, sodium butyr-
ate or sodium chloride for 2 h. Then, HDAC-Glo™ I/II
Reagent was added, and the luminescence was directly
measured using a chemiluminescence plate reader after
a 30-min incubation at room temperature.
Western blot analysis
The histone acetylation status of HeLa cells was evaluated
after 24 h incubation in lactate or butyrate. The harvested
cells were washed twice with ice-cold phosphate-buffered
saline (PBS) supplemented with either lactate (10 or
20 mM) or butyrate (5 mM) and centrifuged at 400 g for
8 min at 4 °C. Then, the cells were suspended in Triton
extraction buffer (TEB: PBS containing 0.5 % Triton
X-100 (v/v), 2 mM PMSF, and 0.02 % (v/v) NaN3) at a
density of 1 × 106 cells/100 μl and lysed on ice for 10 min.
After centrifugation at 6500 g for 10 min, the pellet was
washed with a half volume of TEB, suspended in 0.2 N
HCl at a density of 3 × 106 cells/70 μl, and incubated at
4 °C overnight for acidic extraction. The next day, the
samples were centrifuged, and the extracts were neutra-
lised with a 1/50 volume of 10 N NaOH, followed by SDS-
PAGE (NuPAGE gradient gel 4–12 %, Life Technologies)
and transfer to a nitrocellulose membrane. After 1 h of
blocking (SuperBlock Blocking Buffer, Thermo Fisher
Scientific, Inc., Waltham, MA, USA) and overnight incu-
bation at 4 °C in anti-acetyl-H3 and -H4 primary anti-
bodies (#39140 and #39967, Active Motif, Carlsbad, CA,
USA), the membrane was washed with TBS and incubated
in an HRP-conjugated secondary antibody (Dako, Ely,
UK) for 1 h at RT. Antibody binding was visualised via
chemiluminescence using SuperSignal West Pico Sub-
strate (Thermo Fisher Scientific, Inc.). The membrane
was stripped and re-probed with anti-H3 and -H4
primary antibodies (#39763 and #61300, Active Motif )
for 1 h at RT as described above. The experimental design
for evaluating the HCAR1 protein level and Erk phosphor-
ylation was as described above with minor changes. For
analysis of the HCAR1 protein level, cells grown at 70 %
confluence were harvested using a cell scraper, centrifuged
and lysed with RIPA buffer supplemented with a protease
inhibitor cocktail (Roche Diagnostics GmbH). For Western
blot analysis of Erk phosphorylation, HeLa cells that were
serum-starved (DMEM, 0.5 % FBS) overnight were stimu-
lated with lactate for 5 min in the presence or absence of
100 ng/ml PTX (overnight pretreatment) or 10 μM of the
MAPK inhibitor U0126 (2 h pretreatment). The cells were
harvested using a cell scraper, centrifuged and lysed with
PhosphoSafe Extraction Reagent (Novagen, EMD Chemi-
cals, CA, USA) containing a protease inhibitor cocktail
(Roche). The primary antibodies used were anti-GPR81
(ab106942, Abcam, Cambridge, UK), anti-p-Erk1/2, anti-
Erk and anti-β-actin conjugated to HRP (sc-101760, sc-94
and sc-1616, respectively, Santa Cruz Biotechnology, Inc.).
The membrane handling and incubation conditions were
as described above. Chemiluminescence signals were cap-
tured and quantified using a G:BOX gel imager (Syngene,
Cambridge, UK).
Quantification of DNA compactness
Cells grown on a 96-well plate were washed with ice-
cold PBS, fixed in 4 % formaldehyde for 20 min and
washed twice with PBS. After the final PBS wash, the
cells were stained with 1 μg/ml of Hoechst 33,342 solution
in PBS for 10 min and subjected to analysis using an
ArrayScan VTI HCS Reader (Thermo Fisher Scientific,
Inc.) equipped with a 40× objective. To visually assess
changes in chromatin structure after lactate or butyrate
treatment, representative images were subjected to Sobel
edge detection and thresholding using ImageJ software.
The process of chromatin expansion decreases the num-
ber of distinct spaces within the nucleus, and these
changes can be visualised via the detection of the Sobel
edges as shown by Irianto and co-workers [30]. Quantita-
tive analysis of chromatin compactness was performed by
calculating the CV for the Hoechst intensity of all pixels
within individual nuclei according to the method de-
scribed by Contrepois and co-workers [31]. The Target
Activation Bioapplication software (Thermo Fisher Scien-
tific, Inc.) was set up to analyse 100 cells per well and to
calculate the mean fluorescence and standard deviation of
Hoechst staining within each nucleus. The CV parameter
was obtained by dividing the standard deviation by the
mean fluorescence. Each experiment was performed in six
replicates.
DNA DSB repair assay
DNA DSB repair was measured via a neutral comet
assay as previously described [32] using a Comet Assay
Kit (Trevigen, Gaithersburg, MD, USA). Comets were
stained with SYBR Green I, visualised using a Nikon D-
Eclipse Ti fluorescence microscope (5× objective) and
analysed using CASP software [33].
Colony formation assay
Actively growing cells in flasks were incubated in the
presence or absence of lactate for 24 h before treatment
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with chemotherapeutics for the next 24 h. Then, the
cells were harvested via trypsinisation, seeded in 10-cm-
diameter Petri dishes at densities ranging from 500 to
400,000 per dish in triplicate in drug-free medium and
then allowed to form colonies. After 14 days, the col-
onies were fixed in Carnoy’s solution and stained with
crystal violet. Images of the dishes were captured using a
G:BOX imager and processed using ImageJ software,
which was set up to count colonies containing > 50 cells.
The SIF was calculated by dividing the SF of cells treated
with a cytotoxic agent and lactate by the SF of cells
treated with a cytotoxic agent alone. The SF values used
to determine the SIF were calculated using the linear
quadratic model [SF = exp(−aD-bD2)] in GraphPad
Prism software according to the least-squares fit.
γ-H2AX, phospho-DNA-PKcs and HCAR1
immunocytochemistry
Cells grown on a 96-well plate were washed with ice-
cold PBS and fixed with ice-cold methanol:acetone (1:1)
for 20 min at −20 °C. After the blocking procedure (1 %
BSA in PBST, 1 h), the cells were stained with a rabbit
antibody against γ-H2AX (ab2893, Abcam, Cambridge,
UK) at 4 °C overnight in a humidified chamber. Primary
antibody binding was visualised using an Alexa Fluor
594-conjugated goat anti-rabbit antibody (Life Technolo-
gies) followed by nuclear staining with 1 μg/ml Hoechst
33342 for 20 min. The plate was analysed using an
ArrayScan VTI HCS Reader equipped with a 40× object-
ive. Images of 20 fields per well were routinely acquired,
and 150 cells/well were analysed using Spot Detector
Bioapplication V3 software. Each experiment was per-
formed in triplicate. The experimental design for evalu-
ating DNA-PKcs phosphorylation was as described
above with minor changes. The cells were fixed (4 % for-
maldehyde, 20 min), permeabilised (0.25 % Triton X-100
in PBS, 10 min) and blocked (3 % BSA in PBST, 30 min)
before incubation in an anti-pS2056-DNA-PKcs anti-
body (ab18192, Abcam) as the primary antibody over-
night at 4 °C. Images were acquired using an ArrayScan
VTI HCS Reader equipped with a 20× objective and
analysed using Spot Detector Bioapplication V3 software
(p-DNA-PKcs, 250 cells/well). Each experiment was per-
formed in six replicates. For cell surface HCAR1 stain-
ing, cells grown on Lab-Tek chamber slides (Nunc,
Thermo Fisher Scientific, Inc.) were washed with HBSS
and incubated in an anti-FKSG80 antibody (sc-32647,
Santa Cruz Biotechnology, Inc.) in HBSS at 4 °C for
60 min. After fixation with 4 % formaldehyde and block-
ing with 5 % normal donkey serum in PBS for 30 min,
the cells were incubated in an Alexa Fluor 488-
conjugated anti-goat secondary antibody (Invitrogen) at
RT for 1 h and stained with Hoechst 33342. Images were
acquired using a confocal microscope (Nikon D-Eclipse
C-1 Plus) equipped with a 63× objective.
Real time-PCR
Total RNA was extracted from cells using TRIzol reagent
(Sigma-Aldrich) according to the manufacturer’s instruc-
tions. Then, total RNA (5 μg) was reverse-transcribed using
a Maxima First Strand cDNA Synthesis Kit for RT-qPCR
(Thermo Fisher Scientific, Inc.). PCR was performed using
LightCycler 480 SYBR Green I Master Mix (Roche
Diagnostics GmbH, Mannheim, Germany) and a Roche
LightCycler 480 Instrument (Roche Diagnostics GmbH).
Relative gene expression was normalised to the housekeep-
ing genes hydroxymethylbilane synthase (HMBS) and hypo-
xanthine phosphoribosyl transferase (HPRT) and were
calculated using the ΔΔCt method. In total, 5 reference
genes (GAPDH, ACTB, HPRT, HBMS, TBP) were tested
and Normfinder [34] was used to identify the most stably
expressed housekeeping genes (stability values: GAPDH:
0.153, ACTB: 0.240, HPRT: 0.091, HBMS: 0.095, TBP:
0.115).The study of mRNA expression included the follow-
ing genes: LIG3, XRCC1, PNKP, PARP1, PARP2, RAD51,
BRCA1, BRCA2, RAD50, MRE11A, NBS1, XRCC6, XRCC5,
PRKDC, LIG4, XRCC4, DCLRE1C, WRN, NHEJ1, ATM,
ATR, TP53, APTX, PARD3, MDC1, MCT1, MCT2, MCT4,
and HCAR1. The primer sequences are listed in Additional
file 10.
cAMP accumulation assay
The day before the experiment, the culture medium was
replaced with serum-free medium. All experiments were
conducted in the presence of the phosphodiesterase in-
hibitor IBMX at 500 μM. For the cAMP accumulation
studies, HeLa cells were treated with 10–20 mM L- or
D-lactate in the presence of forskolin (10 μM) to stimu-
late cAMP synthesis. The reaction was incubated at 37 °C
for 30 min and then terminated via two cold PBS washes,
immediately followed by cell harvesting using a cell
scraper. The centrifuged cells were resuspended in lysis
buffer, and the measurement of the intracellular cAMP
levels was performed using a cAMP assay kit (R&D
Systems). The data are presented as the means ± SEM of
at least three separate experiments.
Short hairpin RNA
shRNA (Dharmacon, Lafayette, CO, USA) was used to
silence HCAR1 according to the protocol provided by
the manufacturer. Briefly, 24 h before transfection, HeLa
cells were seeded on 24-well plates at a density of 5 × 104
cells/well. Next, the cells were transfected with 1 μg of
HCAR1 shRNA plasmid DNA using 2 μl of TurboFect
Transfection Reagent (Life Technologies) in serum-free
DMEM. Control cells were treated with non-targeted
shRNA (Dharmacon). The next day, the medium was
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replaced with DMEM containing 10 % FBS and puro-
mycin (7.5 μg/ml) (Life Technologies), and the selection of
cells expressing the transgene was continued for 3 weeks,
and the selection medium was changed every 3 days. Re-
sultant puromycin-resistant and GFP-positive cells were
evaluated for HCAR1 expression via real-time PCR and
Western blot.
Statistical analysis
The experiments were repeated at least three times, each
of which was conducted in three or six replicates (except
for Western blot analysis). The data are presented as the
means ± SEM. GraphPad Prism software was used to
analyse and plot the data. Statistical significance was
evaluated using Student’s t-test or one-way ANOVA
followed by Tukey’s test.
Additional files
Additional file 1: Figure S1A. γ-H2AX foci immunolabelling after
neocarzinostatin treatment. Cells were incubated in the presence or
absence of 20 mM L- or D-lactate for 24 h, followed by treatment with 2
nM for 30 min. Then, the cells were allowed to recover for the indicated
period prior to fixation and γ-H2AX staining. Representative images for
the respective treatments are shown. (PDF 255 kb)
Additional file 2: Figure S1B. γ-H2AX foci immunolabelling after
doxorubicin treatment. Cells were incubated in the presence or absence
of 20 mM L- or D-lactate for 24 h, followed by treatment with 2 μM DOX
for 30 min. Then, the cells were allowed to recover for the indicated
period prior to fixation and γ-H2AX staining. Representative images for
the respective treatments are shown. (PDF 456 kb)
Additional file 3: Figure S1C. γ-H2AX foci immunolabelling after
cisplatin treatment. Cells were incubated in the presence or absence of
20 mM L- or D-lactate for 24 h, followed by treatment with 20 μM CDDP
for 30 min. Then, the cells were allowed to recover for the indicated
period prior to fixation and γ-H2AX staining. Representative images for
the respective treatments are shown. (PDF 322 kb)
Additional file 4: Figure S2A. DNA repair in HeLa cells after exposure
to neocarzinostatin. Cells were incubated in the presence or absence of
20 mM L- or D-lactate for 24 h, followed by treatment with 5 nM NCS for
30 min. Then, the cells were allowed to recover for the indicated period
prior to harvesting for the neutral comet assay. Each image shows a
representative area of a microscopic slide for the particular treatment
from the same experiment. (PDF 156 kb)
Additional file 5: Figure S2B. DNA repair in HeLa cells after exposure
to doxorubicin. Cells were incubated in the presence or absence of
20 mM L- or D-lactate for 24 h, followed by treatment with 2 μM DOX
for 30 min. Then, the cells were allowed to recover for the indicated
period prior to harvesting for the neutral comet assay. Each image shows
a representative area of a microscopic slide for the particular treatment
from the same experiment. (PDF 123 kb)
Additional file 6: Figure S2C. DNA repair in HeLa cells after exposure
to cisplatin. Cells were incubated in the presence or absence of
20 mM L- or D-lactate for 24 h, followed by treatment with 20 μM CDDP
for 30 min. Then, the cells were allowed to recover for the indicated
period prior to harvesting for the neutral comet assay. Each image shows
a representative area of a microscopic slide for the particular treatment
from the same experiment. (PDF 140 kb)
Additional file 7: Figure S3. Hela cells incubated in the presence of
L-lactate or D-lactate show higher nuclear DNA-PKcs immunoreactivity.
HeLa cells were incubated in the presence or absence of 20 mM L-lactate
or 20 mM D-lactate for 24 h. Then, fixed and permeabilised cells were
stained with anti-DNA-PKcs antibody (sc-9051, Santa Cruz Biotechnology,
Inc.), followed by incubation with Alexa Fluor 594-conjugated secondary
antibodies. The data are averaged from three independent experiments
and presented as the means ± SEM of the percentage of cells exhibiting
greater DNA-PKcs nuclear immunoreactivity than the untreated cell
population in three independent experiments. *P < 0.05 and **P < 0.01
indicate significant differences compared to the untreated cells. (PDF 206 kb)
Additional file 8: Figure S4. DNA repair in HeLa cells incubated with
3,5-DHBA. Cells were incubated in the presence or absence of 500 μM
3,5-DHBA for 24 h and followed by treatment with NCS (5 nM) for 30 min.
Then, the cells were allowed to recover for 2 h prior to harvesting for the
neutral comet assay. Each image shows a representative area of a microscopic
slide for the particular treatment from the same experiment. (PDF 83 kb)
Additional file 9: Figure S5. Efficacy of the shRNA against HCAR1. (A)
Quantification of the mRNA expression of HCAR1 in wild type, control
shRNA- and HCAR1 shRNA-expressing HeLa cells. (B) Western blot for
HCAR1 protein expression in wild type, control shRNA- and HCAR1
shRNA-expressing HeLa cells. (PDF 68 kb)
Additional file 10: Table S1. Sequences of the primers used for real-time
PCR. (PDF 8 kb)
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